C2orf70 Inhibitors

C2orf70 Inhibitors encompas a diverse array of compounds targeting specific cellular signaling pathways involved in the regulation of the C2orf70 protein. These inhibitors act through distinct mechanisms, affecting critical components in signaling cascades associated with C2orf70 function. Wortmannin, for instance, interferes with PI3-kinase, disrupting downstream pathways. SB203580 selectively inhibits p38 MAP kinase, influencing pathways pivotal to cellular responses. U0126 hinders MEK1 and MEK2, integral kinases in the MAPK signaling cascade. LY294002, a PI3-kinase inhibitor, perturbs the PI3K/AKT signaling axis.

Rapamycin targets mTOR, disrupting mTOR-dependent cellular processes, while JNK Inhibitor VIII and SP600125 act on c-Jun N-terminal kinase and JNK, respectively, influencing cellular stress responses. PD98059 selectively inhibits MEK1, modulating the MAPK pathway. LY303511, a structural analog of LY294002, offers another avenue to inhibit PI3-kinase. PP2, a Src family kinase inhibitor, impacts cellular functions through Src inhibition. SB431542 disrupts the TGF-β pathway by inhibiting the TGF-β type I receptor. LY2157299 (Galunisertib) serves as a TGF-β receptor inhibitor, affecting TGF-β signaling. This diverse range of inhibitors collectively provides a comprehensive toolkit for researchers aiming to elucidate the intricate role of C2orf70 in cellular processes by selectively manipulating associated signaling pathways.